Background: Recent clinical trials have questioned the necessity of breast radiation therapy for older women with early breast cancer. However, the effectiveness of radiation therapy for older women in the community setting has not been addressed. Methods: We used the Surveillance, Epidemiology, and End Results (SEER) -Medicare database from January 1, 1992, through December 31, 1999, to identify 8724 women aged 70 years or older treated with conservative surgery for small, lymph node -negative, estrogen receptor -positive (or unknown receptor status) breast cancer. We used a proportional hazards model to test whether radiation therapy was associated with a lower risk of a combined outcome, defi ned as a second ipsilateral breast cancer reported by SEER and/ or a subsequent mastectomy reported by Medicare claims. All statistical tests were two-sided. Results: Radiation therapy, compared with no radiation therapy, was associated with a lower risk of the combined outcome (hazard ratio = 0.19, 95% confi dence interval = 0.14 to 0.28). Radiation therapy was associated with an absolute risk reduction of 4.0 events per 100 women at 5 years (i.e., from 5.1 events without radiation therapy to 1.1 with radiation therapy) and 5.7 events per 100 persons at 8 years (i.e., from 8.0 events without radiation therapy to 2.3 with radiation therapy) ( P <.001, log-rank test). 
For many years, breast radiation therapy after conservative surgery has been a standard of care for patients with early breast cancer ( 1 -4 ) . However, a recent randomized trial from the Cancer and Leukemia Group B (trial C9343) explored whether breast radiation therapy was necessary in those aged 70 years and older with small, estrogen receptor (ER) -positive (or unknown ER status), clinically lymph node -negative breast cancer treated with conservative surgery and tamoxifen ( 5 ) . Although radiation therapy conferred a statistically signifi cant reduction in the risk of local -regional relapse, the absolute risk reduction was only three events per 100 persons at 5 years of follow up.
Given the small absolute benefi t of radiation therapy, coupled with its cost ( 6 ) and morbidity ( 5 ) , new clinical guidelines have recommended omission of breast radiation therapy for women who meet the entry criteria for trial C9343 ( 7 ) . Although meaningful differences may exist between patients who enroll in clinical trials and those in the general population ( 8 -11 ) , the effectiveness of breast radiation therapy in the community setting has not been addressed ( 12 ) . Identifi cation of those who are most -and least -likely to benefi t from breast radiation therapy would allow clinicians to tailor their treatment recommendations appropriately.
To address these critical issues, we identifi ed patients in the Surveillance, Epidemiology, and End Results (SEER) -Medicare database who would have been eligible for the C9343 trial. We investigated whether radiation therapy was associated with a lower risk of a second breast cancer event -i.e., a combined outcome defi ned as a second ipsilateral breast cancer as reported by SEER and/or a subsequent mastectomy as reported by Medicare claims.
P ATIENTS AND M ETHODS

Data Source
The National Cancer Institute's SEER -Medicare database tracks incident malignancies in Medicare benefi ciaries, linking tumor-specifi c variables coded by local SEER registries to Medicare claims. During the study period of January 1, 1992, through December 31, 1999 , data were available from 11 tumor registries representing approximately 14% of the United States' population ( 13 ) .
Study Sample and Outcomes
From 1992 through 1999, 60 717 women aged 70 years or older with breast cancer were identifi ed in the database. The following women were excluded because they would not have met entry criteria for trial C9343: tumor size not reported or greater than 2.0 cm (26 161 patients excluded); no invasive component (6679 patients excluded); histology not consistent with epithelial origin (1355 patients excluded); clinical stage T4 (5004 patients excluded); ER-negative status (6454 patients excluded); involved regional lymph nodes (13 799 patients excluded); distant metastasis at presentation (3332 patients excluded); stage not reported (2611 patients excluded); not treated with breast-conserving surgery (33 859 patients excluded); history of prior malignancy (1706 patients excluded); bilateral disease (51 patients excluded); and disease not pathologically confi rmed (1797 women excluded). Thus, 13 319 patients met all clinical entry criteria (patients could also be excluded for more than one reason; a total of 9413 patients were excluded solely because of treatment with mastectomy).
Within this clinical group, patients with a second primary cancer diagnosed within 9 months after the index primary were excluded (435 patients) because billing records could not discriminate between procedures performed for the index cancer versus the second cancer. Patients with inadequate Medicare records (641 patients without Part A and B Medicare coverage and 3547 patients without fee-for-service coverage from 12 months before diagnosis to 9 months after diagnosis) were also excluded, leaving 8932 patients with adequate baseline Medicare claims (patients could, again, be excluded for more than one reason).
Cancer-specifi c treatments received within 9 months of initial diagnosis were considered to represent treatment for the index cancer ( 14 ) . A sensitivity analysis tested whether inclusion of treatments received within only 6 months or up to 12 months after initial diagnosis would alter the study results. The follow-up period began 9 months after diagnosis and continued through December 31, 2002 . The primary outcome -a second breast cancer event -was a combined outcome defi ned as a second ipsilateral, pathologically confi rmed, invasive breast cancer reported by SEER and/or a subsequent mastectomy reported by Medicare claims. The secondary outcome was risk of repeat breast-conserving surgery reported by Medicare claims. Breastconserving surgery was not included in the primary outcome because it may be performed to rule out cancer and is, therefore, not specifi c for local relapse.
Medicare claims do not consistently report laterality for breast surgical procedures. Because laterality is important in establishing a second ipsilateral versus contralateral event, we excluded two patients with unknown laterality at initial diagnosis and 206 patients reported by SEER as experiencing any contralateral breast event in the follow-up period. The fi nal cohort therefore included 8724 patients aged 70 years or older who were treated with conservative surgery for small, lymph node -negative, invasive breast cancer that was ER -positive (or of unknown ER status). A sensitivity analysis tested whether inclusion of patients with contralateral breast events would alter the study results. ( 14 , 16 -20 ) . Patients were considered to have received radiation therapy if either SEER or Medicare reported treatment with radiation therapy within 9 months of diagnosis. Treatment with chemotherapy within 9 months of diagnosis was determined from Medicare claims (ICD-9 Procedure Code 99.25; ICD-9 Diagnosis Codes V58.1, V66.2, or V67.2; Current Procedural Terminology Codes 96400 -96549; Health Care Procedure Coding System Codes J9000 -J9999 or Q0083 -Q0085; or Revenue Center Codes 0331, 0332, or 0335) ( 16 -19 , 21 , 22 ) . The method of axillary lymph node assessment was determined from SEER data (pathologic assessment if at least one lymph node was sampled, otherwise a clinical assessment).
Treatment-Related Variables
Other Variables
Patient characteristics included age at diagnosis, race (white, black, white Hispanic, Asian/Pacifi c Islander, or other/unknown), year of diagnosis, marital status (widowed, married, single, separated/divorced, or unknown), SEER registry, urban versus rural residence (big metropolitan, metropolitan, urban, less urban, or rural), median income of census tract or zip code (census tract data were used if available, otherwise zip code data were used) ( 23 ) , percentage of adults in census tract or zip code with less than 12 years education (census tract data were used if available, otherwise zip code data were used) ( 23 ) , and number of physician visits on separate days during a prediagnosis interval from 12 months to 1 month. Distance from the patient's zip code to the nearest radiotherapy facility was calculated from radiotherapy facility zip codes provided by the American College of Radiology (ZIPFind Deluxe 5.0, Xionetic Technologies, Inc., Bozeman, MT). A modifi ed Charlson comorbidity index ( 24 -26 ) was calculated from Part A and Part B Medicare claims during a prediagnosis interval from 12 months to 1 month. To enhance specifi city, Part B diagnosis codes were included only if they appeared more than once over a period of more than 30 days or in Part A claims as well ( 27 , 28 ) .
Tumor characteristics included size, location within the breast (inner quadrant, outer quadrant or central, overlapping, or unknown) ( 29 ) , grade (well differentiated, moderately differentiated, poorly or undifferentiated, or unknown), histology (ductal, lobular, or other) ( 30 ) , ER status (positive, borderline, negative, or unknown, as reported by SEER), progesterone receptor status (positive, borderline, negative, or unknown, as reported by SEER), and laterality (right or left). Hospital characteristics included teaching status (yes or no), which was self-reported in the Hospital Cost Report Information Systems fi les available for 1996, 1998, and 2000 ( 31 ) . Data regarding surgical margin status and adjuvant endocrine therapy were not reported by SEERMedicare. All variables are summarized in Appendix A .
Statistical Analysis
Because the risk of local relapse at 5 and 8 years is a commonly reported endpoint in breast cancer clinical trials ( 3 -5 , 32 , 33 ) , the unadjusted risk of each outcome at 5 and 8 years was estimated by use of the Kaplan -Meier method. The KaplanMeier method was selected to provide estimates that could be directly compared with the results of trial C9343. Unadjusted associations between radiation therapy and outcomes were tested by use of the log-rank test. Patients were censored at the time of death, loss of Medicare Part A or B coverage, or loss of fee-forservice coverage. If none of these events occurred, patients were censored at the end of the follow-up period, December 31, 2002 .
The hazard functions of the groups receiving radiation therapy or no radiation therapy were approximately parallel, indicating that the proportional hazards assumption was satisfi ed. Therefore, the adjusted relationship between breast radiation therapy and local relapse was determined with a Cox proportional hazards model adjusted for patient, tumor, treatment, and hospital covariates that were considered statistically signifi cant at a P value of less than or equal to .25 in unadjusted analyses. Clinically relevant covariates including age at diagnosis, tumor size, histology, ER status, comorbidity, and treatment with chemotherapy were included in the fi nal model, regardless of their unadjusted P values. Covariates lacking linear relationships with the outcome were entered as categorical (dummy) variables, with missing values as a dummy category. The model was stratifi ed by SEER region and the year of diagnosis to account for variations with geography and time. Prespecifi ed interaction terms were used to determine whether the effect of radiation therapy differed with respect to age, comorbidity, tumor size, histology, and ER status.
The adjusted number needed to treat (NNT) indicates the number of patients who require breast radiation therapy to prevent one local relapse and accounts for the competing risk of death from any cause. The adjusted NNT was calculated by dividing the unadjusted NNT by the survival probability point estimate ( 34 ) . The unadjusted NNT is the reciprocal of the absolute risk reduction estimated with the Kaplan -Meier method. This method assumes that radiation therapy does not affect overall survival through 8 years of follow-up, an assumption that is supported by the results of trial C9343 and other clinical trials ( 3 -5 , 32 ) . For example, if radiation therapy conferred a 4% absolute improvement (unadjusted) in the risk of local relapse at 5 years and if 50% of patients were alive at 5 years, then the unadjusted NNT would be 25 patients (i.e., 1/0.04), and the adjusted NNT would be 50 patients (i.e., 25/0.50).
All statistical analyses were two-sided with an α value of less than or equal to .05 and were conducted with SAS version 9.1 (SAS Institute, Cary, NC). The Yale School of Medicine Institutional Review Board approved this study and granted a waiver of informed consent.
Comparison Cohort
To determine whether the benefi t associated with radiation therapy was sensitive to the eligibility criteria for trial C9343, we formed a comparison cohort consisting of patients who failed to meet the entry criteria for trial C9343 because their age was 66 -69 years, their tumor size was 2.1 -5.0 cm, or their tumor was ER negative. For each subgroup in the comparison cohort, the unadjusted risk of a second breast cancer event and the absolute risk reduction associated with radiation therapy were calculated by use of the Kaplan -Meier method.
R ESULTS Baseline Characteristics
Of the 8724 patients identifi ed, median age was 77 years (interquartile range [IQR] = 73 to 82 years), 7842 (90%) were white, and 365 (4%) were black. Median tumor size was 1.0 cm (IQR = 0.8 to 1.5 cm), 6353 (73%) had ductal histology, and 1789 (21%) had unknown ER status. Comorbidity was absent in 5666 (65%), mild in 1916 (22%), moderate to severe in 884 (10%), and unknown in 258 (3%). A total of 6360 patients (73%) received breast radiation therapy and 255 (3%) received chemotherapy. Treatment with radiation therapy was associated with younger age, lack of comorbid illness, treatment with chemotherapy, and pathologic axillary lymph node assessment ( Table 1 ) . Concordance between SEER and Medicare claims was high for both radiation therapy ( κ = .79) and surgery ( κ = .90).
Unadjusted Risk of Primary and Secondary Outcomes
Median follow-up was 5.0 years (IQR = 3.5 to 7.0 years). Of the 8724 patients included in the analysis, 84 patients (1.0%) experienced a second ipsilateral breast cancer reported by SEER * Radiation therapy was defi ned as any billing code for radiation therapy present in Medicare claims within 9 months of diagnosis or any treatment with radiation therapy reported by SEER data.
† P value from two-sided Pearson's chi-square test, unless otherwise specifi ed. All statistical tests were two-sided.
‡ Data are years (interquartile range). § P value from two-sided Wilcoxon rank-sum test. || Data are centimeters (interquartile range).
¶ In concert with SEER-Medicare guidelines, cell sizes with an absolute number of cases of less than fi ve have been suppressed. data, and 166 patients (1.9%) underwent subsequent mastectomy as reported by Medicare claims. Radiation therapy was associated with a reduced risk for a second ipsilateral breast cancer ( P <.001, Fig. 1 , A , and Table 2 ), subsequent mastectomy ( P <.001, Fig. 1 , B , and Table 2 ) , and the combined outcome of either a second ipsilateral breast cancer and/or subsequent mastectomy (i.e., a second breast cancer event) ( P <.001, Fig. 1 , C , and Table  2 ). At 5 years, the risk of a second breast cancer event was 5.1% (95% confi dence interval [CI] = 4.1 to 6.2) in patients receiving no radiation therapy and 1.1% (95% CI = 0.79 to 1.4) in patients treated with radiation therapy ( Table 2 ) . At 8 years, the risk of a second breast cancer event increased to 8.0% (95% CI = 6.2 to 9.8) in patients receiving no radiation therapy and 2.3% (95% CI = 1.7 to 2.9) in patients treated with radiation therapy ( Table 2 ) . Of the 8724 patients included in the analysis, 794 (9%) patients underwent repeat breast-conserving surgery. Radiation therapy was not associated with risk of this outcome ( P = .83) ( Fig. 1, D ) .
Adjusted Analysis
After adjusting for patient, tumor, treatment, and hospital characteristics, breast radiation therapy remained associated with a reduced risk of a second breast cancer event (the combined outcome) (hazard ratio [HR] = 0.19, 95% CI = 0.14 to 0.28; P <.001; Table 3 ). Radiation therapy was also associated with a reduced risk for each component of the combined outcome (for a second ipsilateral breast cancer reported by SEER, HR = 0.13, 95% CI = 0.07 to 0.23; P <.001; and for subsequent mastectomy reported by Medicare, HR = 0.21, 95% CI = 0.14 to 0.31; P <.001) ( Table 4 ). The effect size associated with radiation therapy was stable regardless of whether the model was unadjusted, adjusted only for age, or fully adjusted ( Table 4 ) .
Breast radiation therapy was associated with a large benefi t for those with lobular histology ( P interaction = .02), with an 8-year second breast cancer event risk of 16% (95% CI = 5.5 to 27) in patients receiving no radiation therapy, compared with a risk of 0.38% (95% CI = 0.00 to 1.1) in patients treated with radiation therapy (adjusted HR = 0.018, 95% CI = 0.002 to 0.14; P <.001). Besides radiation therapy, other covariates associated with a second breast cancer event included being a member of the black race compared with being white (HR = 2.22, 95% CI = 1.18 to 4.21; P = .01), having a widowed marital status compared with having a married marital status (HR = 0.69, 95% CI = 0.49 to 0.97; P = .03), and having a progesterone receptornegative status compared with having a positive status (HR = 1.49, 95% CI = 1.00 to 2.22; P = .05). Age, comorbidity, tumor size, and ER status were not associated with risk of a second breast cancer event, and the interaction of radiation therapy with these variables was not statistically signifi cant. In a sensitivity analysis, the adjusted relationship between radiation therapy and risk of a second breast cancer event was not altered by Fig. 1 . Association of radiation therapy with outcomes. Patients were at risk for all outcomes beginning 9 months after diagnosis. A ) Second ipsilateral breast cancer reported by Surveillance, Epidemiology, and End Results (SEER). This outcome was defi ned as a second ipsilateral, pathologically confi rmed, invasive breast cancer reported by SEER data. B ) Subsequent mastectomy reported by Medicare claims. This outcome is defi ned as a subsequent mastectomy reported by Medicare claims. C ) Second breast cancer event defi ned as a second ipsilateral, pathologically confi rmed, invasive breast cancer reported by SEER data or as a subsequent mastectomy reported by Medicare claims. D ) Repeat breast-conserving surgery as reported by Medicare claims. This outcome is defi ned as repeat breast-conserving surgery reported by Medicare claims. RT = radiation therapy. Error bars = 95% confi dence intervals. * P values were calculated from a two-sided log-rank test. 
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Among women who met the entry criteria for trial C9343, the absolute risk reduction associated with radiation therapy increased over time. At 5 years, the absolute risk reduction was 4.0 events (95% CI = 2.9 to 5.1) per 100 patients (i.e., from 5.1 events without radiation therapy to 1.1 events with radiation therapy). At 8 years, the absolute risk reduction increased to 5.7 events (95% CI = 3.8 to 7.6) per 100 patients (i.e., from 8.0 events without radiation therapy to 2.3 events with radiation therapy) ( Table 2 ) . Hence, women who lived longer were more likely to benefi t from radiation therapy. For example, among those aged 70 -74 years without comorbid illness, 8-year survival was 84% (95% CI = 83 to 86). This subgroup was most likely to benefi t from radiation therapy, with an adjusted NNT of 21 patients (95% CI = 16 to 31) ( Table 5 ). Other patient groups who were more likely to benefi t from radiation therapy included those aged 75 -79 years without comorbid illness (adjusted NNT = 22 patients, 95% CI = 17 to 33), those aged 70 -74 years with mild comorbidity (adjusted NNT = 24 patients, 95% CI = 18 to 36), those aged 75 -79 years with mild comorbidity (adjusted NNT = 28 patients, 95% CI = 21 to 42), and those aged 80 -84 years without comorbid illness (adjusted NNT = 29 patients, 95% CI = 22 to 43). Patients aged 85 years and older with moderate to severe comorbidity were least likely to benefi t from radiation therapy, with an 8-year survival of 14% (95% CI = 7.2 to 21) and an adjusted NNT of 125 patients (95% CI = 94 to 185) ( Table 5 ) .
Comparison Cohort
The comparison cohort comprised 5551 women who would have been ineligible for the C9343 trial because of being aged 66 -69 years, having a tumor of 2.1 -5.0 cm, or having an ER-negative tumor. When compared with the cohort eligible for trial C9343, the adjusted risk of a second breast cancer event was larger for the cohort ineligible for trial C9343 (HR = 1.5, 95% CI = 1.2 to 1.8; P <.001). However, the interaction term of radiation therapy with eligibility status was not statistically signi fi cant ( P = .17), indicating that the relative benefi t associated with radiation therapy was similar for the eligible and ineligible cohorts.
Although the relative benefi t associated with radiation therapy was similar for both cohorts, the absolute benefi t associated with radiation therapy was greater for the ineligible cohort. At 8 years, the absolute risk reduction was 7.7 events per 100 patients (95% CI = 3.9 to 11) for the ineligible cohort (i.e., from 11.7 events without radiation therapy to 4.0 events with radiation therapy) and 5.7 events per 100 patients (95% CI = 3.8 to 7.6) for the eligible cohort (i.e., from 8.0 events without radiation therapy to 2.3 events with radiation therapy). The benefi t of radiation therapy was present for all subgroups of patients ineligible for trial C9343. For example, among patients aged 66 -69 years, the absolute risk reduction was 10 events per 100 patients at 8 years (95% CI = 2.8 to 17) (i.e., from 13.3 events without radiation to 3.3 events with radiation) ( Fig. 2 ) . Similarly, among patients with a tumor of 2.1 -5.0 cm, the absolute risk reduction was 7.3 events per 100 patients at 8 years (95% CI = 1.2 to 13) (i.e., from 10.9 events without radiation to 3.6 events with radiation) ( Fig. 2 ) . Finally, among patients with ER-negative tumors, the absolute risk reduction was 6.7 events per 100 patients at 8 years (95% CI = -0.02 to 16) (i.e., from 11.3 events without radiation to 4.6 events with radiation) ( Fig. 2 ) .
D ISCUSSION
In this community-based cohort of older women with early breast cancer, the 5-year risk of a second breast cancer event, defi ned as a second ipsilateral breast cancer reported by SEER and/or subsequent mastectomy reported by Medicare, was 5.1% (95% CI = 4.1 to 6.2) in patients treated without radiation therapy and 1.1% (95% CI = 0.79 to 1.4) in patients treated with radiation therapy. These results are remarkably consistent with those of the Cancer and Leukemia Group B C9343 randomized trial, in which the risk of local -regional relapse was 4% (95% CI = 2 to 7) without radiation therapy and 1% (95% CI = 0 to 2) with radiation therapy (Table 2 ) ( 5 ) . However, our results also indicate that patients. This value is comparable to those of other accepted interventions, such as antihypertensive therapy, in which 21 women require 10 years of treatment to prevent one coronary heart disease event ( 35 ) . In contrast, patients of advanced age or with moderate to severe comorbid illness were less likely to experience the benefi t associated with radiation therapy. Identifi cation of patients unlikely to benefi t from radiation therapy will serve to minimize the number of older women unnecessarily exposed to the morbidity ( 5 ) , cost ( 6 ) , and inconvenience of breast radiation therapy. Paradoxically, identifi cation of patients unlikely to benefi t from radiation therapy may also serve to reduce utilization of mastectomy. In this study, 41% of patients were excluded solely because of treatment with mastectomy. Traditionally, mastectomy has been recommended for older women with early breast cancer because it will obviate the need for breast radiation therapy. However, among women unlikely to benefi t from radiation therapy, this indication for mastectomy is no longer relevant; such patients should therefore receive conservative surgery without radiation therapy.
Refi ning the appropriate indications for radiation therapy in older women is a matter of substantial public health importance. In 2005, more than 24 000 women in the United States were diagnosed with a breast cancer that met the inclusion criteria for trial C9343 ( 36 , 37 ) ( Appendix B ). By 2030, when the elderly population is expected to double ( 38 ) , this number will approach 50 000. Given the growing number of elderly cancer patients, future studies should consider the benefi ts of adjuvant therapy in light of the competing risk of death from other causes. Although this approach has not previously been adopted in studying cancer therapy, earlier studies used this approach to estimate the benefi ts of preventive interventions such as antihyperlipidemic therapy ( 39 ) or cancer screening ( 34 ) .
The current study confi rms that being younger than 70 years old, having a tumor of more than 2 cm in diameter, or having an ER-negative tumor (i.e., exclusion criteria outlined in trial C9343) defi ne a patient group at higher risk for a second breast cancer event. In addition, the absolute benefi t associated with radiation therapy was greater for women who would have been excluded from trial C9343. Therefore, although the con clusions of clinical trials are often extrapolated to other patient groups ( 40 ) , radiation therapy should remain a standard of care for women who do not meet the inclusion criteria for trial C9343.
One important contrast between the current study and trial C9343 concerns the role of radiation therapy in preventing subsequent mastectomy. Although radiation therapy, compared with no radiation therapy, was associated with a lower risk of subsequent mastectomy in this population-based cohort, radiation therapy did not lower the risk of subsequent mastectomy in trial C9343. These results suggest that women who do not receive radiation therapy and who subsequently develop an in-breast recurrence may be more likely to undergo mastectomy in the community setting than in the clinical trial setting.
Our study has several limitations. Although treatment with tamoxifen may reduce the risk of local relapse ( 41 , 42 ) , information regarding tamoxifen prescription and compliance are not available in the SEER -Medicare data. During the study period, however, tamoxifen was considered the standard of care ( 43 ) and was prescribed for nearly 90% of older women in the community setting ( 44 ) . Further, in prior studies, rates of tamoxifen pres cription and compliance did not appear to differ substantially between patients treated with and without breast † Patients were at risk for the outcome beginning 9 months after diagnosis. Model is adjusted for all patient, tumor, treatment, and hospital characteristics that were statistically signifi cant in unadjusted analysis at a P ≤ .25. The following variables are included in the model but were not reported because they were not statistically signifi cant and had limited clinical relevance: distance to radiation therapy facility, urban/rural status, median income of census tract, and total number of provider visits in the year preceding diagnosis. Hazard ratios for unknown values are not shown in the table and were not statistically signifi cant for any covariate. Model is stratifi ed by SEER geographic site and year of diagnosis.
‡ Adjusted P values from the Cox model. All statistical tests were two-sided. § Medicare claims reported between 12 months and 1 month before diagnosis were used to identify the presence or absence of 18 noncancer chronic diseases. A weight proportional to the risk of death was assigned to each of these 18 chronic diseases. The Charlson comorbidity score is a sum of these weights ( 24 -26 ) .
important, readily identifi able characteristics can determine which patients are most likely to benefi t from radiation therapy. For example, radiation therapy was associated with a large benefi t among women with lobular histology. In addition, healthy women aged 70 -79 years were more likely to experience the benefi t associated with ra diation therapy, with a NNT of 21 to 22
at Pennsylvania State University on February 27, 2014 http://jnci.oxfordjournals.org/ Downloaded from radiation therapy, indicating that the absence of tamoxifen data should not introduce a large directional bias ( 44 , 45 ) . In addition, the similar event risks in the no-radiation group of the current study and the tamoxifen-only arm of trial C9343 provide reassurance that the absence of tamoxifen data should not introduce a substantial bias. Margin status is also not available in SEERMedicare data. However, these data would probably bias our results toward the null because patients with involved margins may be more likely to receive breast radiation therapy ( 46 ) . Finally, the outcome of a second ipsilateral breast cancer reported by SEER does not capture all in-breast recurrences; therefore, subsequent mastectomy as reported by Medicare claims was used as a marker of in-breast recurrence. Although Medicare claims for mastectomy are highly accurate ( 15 ) , laterality of mastectomy is infrequently reported. Thus, despite the exclusion of patients with contralateral breast cancers reported by SEER, it remains possible that a fraction of mastectomies identifi ed in Medicare claims were performed on the contralateral breast.
Although randomized trials are generally considered to produce the highest level of evidence in clinical research, a recent investigation ( 47 ) asserts that carefully designed observational cohort studies may provide estimates of treatment effects that are highly reproducible and valid. For example, the effect size of breast radiation therapy in this observational study (HR = 0.19, 95% CI = 0.14 to 0.28) is consistent in direction and magnitude with those in a recent meta-analysis conducted on randomized clinical trials of breast radiation therapy (HR = 0.33, 95% CI = 0.29 to 0.38) ( 2 ) . This consistency strengthens the validity of our study conclusions and underscores the importance of observational data when evaluating the role of radiation therapy in the general population.
In the general population of patients aged 70 years or older with small, ER-positive (or of unknown ER status), lymph nodenegative breast cancer, radiation therapy after breast-conserving surgery is associated with a lower risk of a second ipsilateral breast cancer and subsequent mastectomy. For those with lobular histology and for those aged 70 -79 years with minimal comorbidity, the benefi t associated with radiation therapy is similar to that of other accepted medical interventions. For women who do not meet the strict age, size, and hormone receptor criteria outlined for trial C9343, the absolute benefi t of radiation therapy is substantial, and radiation therapy should remain the standard of care. ‡ Defi ned as a billing code for mastectomy appearing in Medicare claims. § Defi ned as a second ipsilateral, invasive, pathologically-confi rmed breast cancer reported by SEER data or a billing code for mastectomy reported in Medicare claims or a billing code for mastectomy appearing in Medicare claims. Fig. 2 . Risk of a second breast cancer event among patients eligible and ineligible for trial C9343. Eight-year event risk without and with radiation therapy is reported for the four mutually exclusive patient groups, including patients eligible for trial C9343, patients ineligible for trial C9343 because of age 66 -69 years, patients ineligible for trial C9343 because of tumor size 2.1 -5.0 cm, and patients ineligible for trial C9343 because of estrogen receptor (ER) -negative status. Patients in each of the ineligible groups, including age 66 -69 years, tumor size 2.1 -5.0 cm, and ER-negative status, meet all the other criteria for trial C9343. Error bars = 95% confi dence intervals. All risks are rounded to two signifi cant digits. 
